针对KRAS和SOS1作为抗瘤剂的PROTACs的概述
Zhiqiu Han1, Qianping Wu1, Hongxin Rao1
1School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, China; Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China; University of Chinese Academy of Sciences, 19 Yuquan Road, Beijing 100049, China.
用PROTAC准KRAS和SOS1为治疗KRAS驱动的癌症提供了一个新的策略. 这种方法旨在克服对现有疗法的耐药性,并解决像G12D和G12V这样的突变.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 克拉斯突变驱动~25%的人类癌症,使其成为一个关键的瘤基因.
- 无七之子1 (SOS1) 在KRAS信号传递中至关重要,也是泛KRAS抑制的目标.
- 目前的KRAS G12C抑制剂面临耐药性,并没有解决其他KRAS突变 (G12D,G12V).
研究的目的:
- 审查专为KRAS和SOS1降解而设计的蛋白质溶解向嵌合体 (PROTAC).
- 探索这些PROTAC的化学结构,设计策略和结构-活动关系 (SAR).
- 总结针对KRAS和SOS1的PROTACs在体外和体内活动.
主要方法:
- 对针对KRAS和SOS1的PROTAC的文献综述.
- 化学结构分析和SAR研究.
- 对PROTAC疗效的体外和体内实验数据的评估.
主要成果:
- 通过PROTAC介导的KRAS和SOS1的降解是一种快速发展的策略.
- 经批准的KRAS G12C抑制剂由于耐药性和突变特异性而表现出局限性.
- PROTACs为克服耐药性和向更广泛的KRAS突变提供了一个潜在的解决方案.
结论:
- 降解KRAS和SOS1的PROTACs代表了对KRAS驱动的癌症的有前途的治疗策略.
- 需要进一步开发以加快这些新型化疗的临床应用.
- 在PROTAC设计中解决挑战和探索机遇对于未来的进步至关重要.
更多相关视频
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
10:44Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
The Ras Gene
Ras is a...
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Abnormal Proliferation
PI3K/mTOR/AKT Signaling Pathway
